Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 12Gastrointestinal 6Thoracic 4Genitourinary 3Breast 3Head & Neck 2Dermatologic 2

Conditions

Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

pembrolizumab 28Nivolumab 13Carboplatin 9Paclitaxel 7Gemcitabine 7Docetaxel 7Cisplatin 7fludarabine 6Cyclophosphamide 6Trastuzumab 5palbociclib 4cemiplimab 4avelumab 4atezolizumab 4Ipilimumab 4Fluorouracil 4Filgrastim 4Drug Therapy 4Cetuximab 4fludarabine phosphate 3epacadostat 3durvalumab 3Taxes 3Oxaliplatin 3Fulvestrant 3zimberelimab 2ulixertinib 2trametinib 2tisotumab vedotin 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Leucovorin × Head & Neck × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡